SCHEMBL2952115

SCHEMBL2952115

Cc1cccc(C)c1-n1nc(N)c2cnc(Nc3ccccc3)nc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WEE1 P30291 5/20 0.57
SRC P12931 2/20 0.48
TNK2 Q07912 7/20 0.47
MERTK Q12866 1/20 0.46
CDK4 P11802 3/20 0.46
CCND3 P30281 3/20 0.46
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2D6 P10635 1/20 0.44
GSK3A P49840 2/20 0.43
GSK3B P49841 2/20 0.43
CCND1 P24385 2/20 0.43
CCND2 P30279 2/20 0.43
CCNB2 O95067 1/20 0.43
CCNE2 O96020 1/20 0.43
CDK1 P06493 1/20 0.43
FGFR1 P11362 1/20 0.43
CCNB1 P14635 1/20 0.43
CCNA2 P20248 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10187855 0.72 BCL6 (0.53) WEE1SRCCDK4CYP1A2CYP3A4
SCHEMBL2955963 0.69 TNK2 (0.70) TNK2
SCHEMBL4701225 0.69 TNK2 (0.49) SRCTNK2CYP3A4MEN1TSHR
SCHEMBL31689813 0.68 PKMYT1 (0.60) WEE1CYP3A4CYP2C9CYP2D6CDK1
SCHEMBL31737850 0.67 MERTK (0.55) WEE1MERTKCDK4CCND3CYP1A2
SCHEMBL23853930 0.66 GAA (0.53) WEE1SRCGSK3AGSK3BCDK1
SCHEMBL10187876 0.65 CDK2 (0.53) SRCCDK4CCND3CYP1A2CYP3A4
SCHEMBL20953571 0.65 RAB9A (0.59) SRCCDK4GSK3AGSK3BCCND1
SCHEMBL28743981 0.65 JAK2 (0.56) SRCCDK4CCND3CYP1A2CYP3A4
SCHEMBL29695644 0.65 CDK2 (0.64) SRCCDK4CCND3GSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7763624-B2 Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors AMGEN INC. (US) 2010-07-27 US disclosed
US-20070072851-A1 Pyrazolopyridine and pyrazolopyrimidine compounds AMGEN INC. (US) 2007-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072851-A1 Pyrazolopyridine and pyrazolopyrimidine compounds LCK, MAP4K5, TPMT WEE1 771/4885SRC 64/4885TNK2 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.